Case Study:

33% Revenue

Growth with Named Patient Program

How the Head of Global Market Access for an oral oncolytic was able to increase revenue potential by thinking outside the U.S.


U.S. manufacturer was launching their first product, an oral oncolytic for a rare sub-indication


Forecast in the U.S. was ~ 500 patients


Challenged to increase revenue potential for the brand


Archbow consultant recognized the opportunity for a Named Patient Program (NPP) in EU & ROW markets


Identified & vetted a vendor with EU & ROW capabilities


Established protocol to import product, sell in ex-U.S. markets, collect & report AEs consistently, and communicate with HCPs


By end of year 1, 1/3 of all product sales occurring outside of U.S.


Distribution eventually expanded to multiple markets, including EU, Asia, & South America


All NPP sales counted toward U.S. revenue (top line)


Leveraged market & HCP knowledge to ensure smooth transitions to commercial operations as product was  approved in ex-U.S. markets

Let's Get Social

  • LinkedIn
  • Twitter

© 2020 by Archbow Consulting LLC

(321) 355-2686

4700 Millenia Blvd., Suite 175

Orlando, FL 32839